Clinical Trial Search

Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability

Primary: Number of Participants With Complete Remission (CR) — 68 Participants

Primary: Number of Patients Experiencing Regimen-related Toxicity Events in Study Population — 2; 5 participants

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Complete Remission (CR) — 50; 50; 14; 11 participants

Primary: Asparaginase-Related Toxicity Rate — 26; 28 percentage of participants — p=.60

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Time to Neutrophil Engraftment — 20.0; 22.0 days

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Complete Remission Plus Complete Remission Without Full Platelet Recovery (CR + CRi) — 13 participants

Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants

Primary: Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) — 0 Percentage of participants

Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability

Primary: Number of Participants With Morphological Complete Response Rate — 27; 20 Participants

Primary: Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy — 72.2; 63 Percentage of participants